Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 9/2014

01.09.2014 | Original Article

Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer

verfasst von: Hyun Hoon Chung, Gi Jeong Cheon, Hee Seung Kim, Jae Weon Kim, Noh-Hyun Park, Yong Sang Song

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Using integrated PET/CT, we evaluated the prognostic relevance of preoperative pelvic lymph node (LN) 18F-FDG uptake in endometrioid endometrial cancer.

Methods

We retrospectively reviewed patients with pathologically proven endometrial cancer who underwent preoperative 18F-FDG PET/CT scans to evaluate the prognostic significance of PET/CT parameters and other clinicopathological variables. We used Cox proportional hazards regression to examine the relationship between recurrence and the maximum standardized uptake value (SUVmax) in pelvic LNs (SUVLN) on FDG PET/CT.

Results

Clinical data, treatment modalities and results were reviewed in 70 eligible patients. The median postsurgical follow-up was 29 months (range 6 to 95 months). Receiver-operating characteristic analysis identified the significant SUVLN cut-off value as 15. The SUVLN correlated with FIGO stage (P < 0.001), LN metastasis (P < 0.001), lymphovascular space invasion (P < 0.001), SUVtumour (P = 0.001), metastatic LN size (P = 0.004), primary tumour size (P = 0.012), tumour grade (P = 0.015) and depth of tumour invasion (P = 0.035). Regression analysis showed a statistically significant association between recurrence and SUVLN (P = 0.002). Recurrence differed significantly (P < 0.001) between patients with SUVLN >15 and those with SUVLN ≤15.

Conclusion

Preoperative pelvic LN FDG uptake exhibited a strong significant association with recurrence of endometrioid endometrial cancer.
Literatur
4.
Zurück zum Zitat Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011;22:3–8. doi:10.3802/jgo.2011.22.1.3. Odagiri T, Watari H, Hosaka M, Mitamura T, Konno Y, Kato T, et al. Multivariate survival analysis of the patients with recurrent endometrial cancer. J Gynecol Oncol. 2011;22:3–8. doi:10.​3802/​jgo.​2011.​22.​1.​3.
6.
Zurück zum Zitat Berman ML, Ballon SC, Lagasse LD, Watring WG. Prognosis and treatment of endometrial cancer. Am J Obstet Gynecol. 1980;136:679–88.PubMed Berman ML, Ballon SC, Lagasse LD, Watring WG. Prognosis and treatment of endometrial cancer. Am J Obstet Gynecol. 1980;136:679–88.PubMed
8.
Zurück zum Zitat Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63:825–32.PubMed Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63:825–32.PubMed
9.
Zurück zum Zitat Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116:1141–9. doi:10.1097/AOG.0b013e3181f39849.PubMedCrossRef Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116:1141–9. doi:10.​1097/​AOG.​0b013e3181f39849​.PubMedCrossRef
10.
Zurück zum Zitat Amit A, Schink J, Reiss A, Lowenstein L. PET/CT in gynecologic cancer: present applications and future prospects—a clinician's perspective. Obstet Gynecol Clin North Am. 2011;38:1–21, vii. doi: 10.1016/j.ogc.2011.02.001. Amit A, Schink J, Reiss A, Lowenstein L. PET/CT in gynecologic cancer: present applications and future prospects—a clinician's perspective. Obstet Gynecol Clin North Am. 2011;38:1–21, vii. doi: 10.​1016/​j.​ogc.​2011.​02.​001.
11.
Zurück zum Zitat Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34:392–404. doi:10.1007/s00259-006-0224-1.PubMedCrossRef Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34:392–404. doi:10.​1007/​s00259-006-0224-1.PubMedCrossRef
12.
Zurück zum Zitat Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53–8. doi:10.1006/gyno.2002.6606.PubMedCrossRef Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53–8. doi:10.​1006/​gyno.​2002.​6606.PubMedCrossRef
13.
Zurück zum Zitat Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol. 1993;51:197–204. doi:10.1006/gyno.1993.1272.PubMedCrossRef Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol. 1993;51:197–204. doi:10.​1006/​gyno.​1993.​1272.PubMedCrossRef
14.
Zurück zum Zitat Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [18F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012;39:840–5. doi:10.1007/s00259-011-2057-9.PubMedCrossRef Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [18F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012;39:840–5. doi:10.​1007/​s00259-011-2057-9.PubMedCrossRef
18.
Zurück zum Zitat Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, et al. FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun. 2006;27:481–7.PubMedCrossRef Torizuka T, Nakamura F, Takekuma M, Kanno T, Ogusu T, Yoshikawa E, et al. FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun. 2006;27:481–7.PubMedCrossRef
19.
Zurück zum Zitat Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:74–80. doi:10.1007/s00259-010-1614-y.PubMedCrossRef Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:74–80. doi:10.​1007/​s00259-010-1614-y.PubMedCrossRef
20.
Zurück zum Zitat Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer. 2010;116:1469–75. doi:10.1002/cncr.24972.PubMedCrossRef Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer. 2010;116:1469–75. doi:10.​1002/​cncr.​24972.PubMedCrossRef
21.
Zurück zum Zitat Chung HH, Cheon GJ, Kang KW, Kim JW, Park NH, Song YS. Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer. Eur J Nucl Med Mol Imaging. 2014;41:674–81. doi:10.1007/s00259-013-2626-1.PubMedCrossRef Chung HH, Cheon GJ, Kang KW, Kim JW, Park NH, Song YS. Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer. Eur J Nucl Med Mol Imaging. 2014;41:674–81. doi:10.​1007/​s00259-013-2626-1.PubMedCrossRef
22.
Zurück zum Zitat Kitajima K, Murakami K, Yamasaki E, Fukasawa I, Inaba N, Kaji Y, et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol. 2008;190:1652–8. doi:10.2214/AJR.07.3372.PubMedCrossRef Kitajima K, Murakami K, Yamasaki E, Fukasawa I, Inaba N, Kaji Y, et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol. 2008;190:1652–8. doi:10.​2214/​AJR.​07.​3372.PubMedCrossRef
23.
Zurück zum Zitat Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol. 2008;108:486–92. doi:10.1016/j.ygyno.2007.11.044.PubMedCrossRef Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol. 2008;108:486–92. doi:10.​1016/​j.​ygyno.​2007.​11.​044.PubMedCrossRef
Metadaten
Titel
Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer
verfasst von
Hyun Hoon Chung
Gi Jeong Cheon
Hee Seung Kim
Jae Weon Kim
Noh-Hyun Park
Yong Sang Song
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2775-x

Weitere Artikel der Ausgabe 9/2014

European Journal of Nuclear Medicine and Molecular Imaging 9/2014 Zur Ausgabe